Got $1,000? Here Are My Favorite Nuclear Stocks to Invest in Right Now.

Goldman Sachs is bullish on nuclear, calling SMRs/fusion a potential multi-trillion opportunity as hyperscalers drive commercialization interest. However, both pure-play SMR stocks highlighted—Oklo and NuScale—remain unproven commercially: neither has built a commercial SMR, and prior project cancellations (e.g., a NuScale 2024 customer cancellation) underscore execution risk. The article frames upside as speculative for both names given combined valuations near ~$10B and the industry’s history of failed/paused projects.

Analysis

Public nuclear equities are trading more like call options on power scarcity than businesses with visible cash flows. The near-term winner is the name with the cleanest AI/data-center adjacency, because that story can attract growth capital before a reactor is ever built; the laggard is the one whose path still runs through utility procurement, public-sector permitting, and project finance, where every delay increases dilution risk. The only clear second-order beneficiaries are the scarce-component suppliers and the power-infrastructure stack; the bottleneck is execution capacity, not demand rhetoric.

For the next 1-3 months, price action should be governed by catalyst gaps: partner announcements, permitting milestones, and any evidence of non-dilutive funding. The biggest reversal risk is another project cancellation or an equity raise at a discount; that would compress the entire group because the market is already paying for commercialization optionality, not proven earnings. Over 6-18 months, only binding offtake and final investment decisions matter; if those do not appear, the current premium likely collapses back toward option value.

Contrarian view: consensus is treating regulatory approval and strategic enthusiasm as equivalent to bankable revenue. That is the wrong bridge to cross. GS may pick up some advisory/underwriting optionality if the theme becomes financeable, but this is too indirect to drive a meaningful earnings revision. The cleaner expression is relative value, not outright beta-chasing, and even that only works if you can tolerate binary headline risk.

Key Decisions for Investors

• Pair trade: long OKLO / short SMR for 1-3 months, sized small and entered on any post-headline strength; thesis is faster AI-adjacent monetization versus slower utility-led commercialization. Stop if SMR announces a financed binding utility project or OKLO needs a dilutive raise.
• Do not chase standalone longs in SMR here; wait for either a 15-20% pullback or a first non-dilutive project-finance package before considering entry. Current upside is narrative-driven, while downside is dilution plus timeline slippage.
• If you want nuclear exposure, keep it as convexity only: small OKLO position or call-spread structure rather than core equity. The risk/reward is attractive only if you accept that the stock can re-rate 2x on a contract and de-rate just as fast on financing news.
• Treat GS as a watch item, not a trade: any benefit from nuclear activity is fee-based and too indirect to underwrite today. Revisit only if announced project finance or capital-markets activity becomes material.